Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Vanderbilt University Medical Center · Intradialytic Hypotension
Phase 3
Recruiting
26
2026-04
Evidence dashboardStudies since 2004Updated Jul 31, 2026
IcatibantClinical Trials.
A source-linked view of every Icatibant study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 33
- Recruiting
- 1
- Completed
- 28
- Terminated
- 2
- Results posted
- 14
- Average enrollment
- 126
- Countries
- 29
- Highest phase
- Phase 4
Largest indexed study
1,761 participants · NCT01034969 →Developer / research origin
Shire / Takeda
Evidence summary
Activity is not efficacy.
Icatibant appears in 33 indexed studies: 1 recruiting, 28 completed and 14 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Icatibant is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
QuantumLeap Healthcare Collaborative · COVID-19
Phase 2
Active, not recruiting
1,500
2026-03
NCT IDStudyPhase / statusEnrollmentUpdated
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
32
2026-07
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
115
2026-01
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
Not applicable
Completed
88
2026-01
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Nang Kuang Pharmaceutical Co., Ltd. · Bradykinin-mediated Angioedema · Hereditary Angioedema (HAE)
Phase 4
Completed
5
2025-12
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
Vanderbilt University Medical Center · Heart Failure
Phase 4
Completed
46
2025-08
FIRAZYR General Drug Use-Results Survey (Japan)
Shire · Hereditary Angioedema (HAE)
Not applicable
Completed
179
2025-02
Showing 6 of 28 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Vanderbilt University Medical Center · Heart Failure NYHA Class I · Heart Failure NYHA Class II
Phase 2
Withdrawn
0
2018-01
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
Vanderbilt University Medical Center · ACE Inhibitor-associated Angioedema
Phase 4
Terminated
33
2017-02
Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
Vanderbilt University · Angioneurotic Edema
Phase 1
Terminated
13
2015-12
Full study index
Search Icatibant trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
33 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 35667714 ↗Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD; ISPY COVID Adaptive Platform Trial Network; undefined. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open. 2022 Jun 6;12(6):e060664. doi: 10.1136/bmjopen-2021-060664.Linked from NCT04488081PMID 40462830 ↗Mabrey FL, Martin TR, Calfee CS, Liu KD, LaCombe B, Brown-Swigart L, Discacciati A, Eklund M, Heckbert SR, Matthay MA, Esserman L, Wurfel MM. Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial. CHEST Crit Care. 2025 Mar;3(1):100117. doi: 10.1016/j.chstcc.2024.100117. Epub 2024 Dec 9.Linked from NCT04488081PMID 39592213 ↗Pomponio R, Peterson RA, Owusu M, Slaughter S, Melgar S, Jolley SE, Burnham EL. Phosphatidylethanol measures in patients with severe COVID-19-associated respiratory failure identify a subset with alcohol misuse. Alcohol Clin Exp Res (Hoboken). 2025 Jan;49(1):165-174. doi: 10.1111/acer.15495. Epub 2024 Nov 26.Linked from NCT04488081PMID 36883141 ↗I-SPY COVID Consortium. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. EClinicalMedicine. 2023 Apr;58:101889. doi: 10.1016/j.eclinm.2023.101889. Epub 2023 Mar 3.Linked from NCT04488081PMID 34473343 ↗Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.Linked from NCT04488081PMID 25176015 ↗McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.Linked from NCT04113109PMID 30415601 ↗Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.Linked from NCT04113109PMID 27170530 ↗Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gomez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548. Epub 2016 May 12.Linked from NCT04113109
Related pages
Keep researching Icatibant.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.